glp 1 for sleep apnea insurance companies scrambling to support need GLP-1 drugs - The C.O.R.E. Group Ole Miss researchers study barriers

Implications for weight loss drugmakers: Consumer demand and pressure for lower GLP-1 prices will fuel competition, but Novo and Lilly are well positioned due to their scale

While both medications work to promote weight loss, they differ slightly in their mechanisms and effectiveness

Testimonials are not a guarantee of future results

These administrative barriers can delay treatment initiation and may preferentially restrict access to patients with the most severe disease

This shift indicates a broader trend among insurers, where approximately 60% of plans include medications for obesity-related conditions, though stringent criteria often apply